Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)

633 Background: We previously demonstrated that weekly T + HL after anthracycline based therapy was not feasible due to high incidence of grade (G) 3 diarrhea, which led to modification of the ALTT...